The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Acetylcholinesterase inhibitors: novel activities of old molecules
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Ward, A., & Clissold, S. P. (1987) · Drugs · doi:10.2165/00003495-198734010-00003 · Cited by 1,754
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α
Moss, M. L., Jin, S.-L. C., Milla, M. E., Burkhart, W., Carter, H. L., Chen, W.-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., et al. (1997) · Nature · doi:10.1038/385733a0 · Cited by 1,378
Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., et al. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0811 · Cited by 1,080
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,004
Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., Haass, C., & Fahrenholz, F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3922 · Cited by 975
Buxbaum, J. D., Liu, K.-N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., Johnson, R. S., Castner, B. J., Cerretti, D. P., & Black, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.27765 · Cited by 934
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Evidence that production and release of amyloid beta-protein involves the endocytic pathway
Koo, E. H., & Squazzo, S. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32449-3 · Cited by 829
Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein
Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A., & Tang, J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1456 · Cited by 776
Beta-amyloid precursor protein cleavage by a membrane-bound protease.
Sisodia, S. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.6075 · Cited by 738
HOOPER, N. M., KARRAN, E. H., & TURNER, A. J. (1997) · Biochemical Journal · doi:10.1042/bj3210265 · Cited by 617
Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., & Selkoe, D. J. (1995) · Nature Medicine · doi:10.1038/nm1295-1291 · Cited by 592
Regulation of APP cleavage by α‐, β‐ and γ‐secretases
Nunan, J., & Small, D. H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02076-7 · Cited by 512
beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms.
Haass, C., Hung, A. Y., Schlossmacher, M. G., Teplow, D. B., & Selkoe, D. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53650-4 · Cited by 465
Presynaptic Cholinergic Dysfunction in Patients with Dementia
Sims, N. R., Bowen, D. M., Allen, S. J., Smith, C. C. T., Neary, D., Thomas, D. J., & Davison, A. N. (1983) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1983.tb11311.x · Cited by 422
The cholinergic system in Alzheimer's disease
Kása, P., Rakonczay, Z., & Gulya, K. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00028-2 · Cited by 409
Galantamine: A Review of its Use in Alzheimer??s Disease
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
New Perspectives on Alzheimer's Disease
Price, D. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002421 · Cited by 353
Coyle, J., & Kershaw, P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 335
Skovronsky, D. M., Moore, D. B., Milla, M. E., Doms, R. W., & Lee, V. M.-Y. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2568 · Cited by 328
The amyloid precursor protein of Alzheimer's disease is released by human platelets.
Bush, A. I., Martins, R. N., Rumble, B., Moir, R., Fuller, S., Milward, E., Currie, J., Ames, D., Weidemann, A., & Fischer, P. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55493-4 · Cited by 326
Lilienfeld, S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00221.x · Cited by 309
Enz, A., Amstutz, R., Boddeke, H., Gmelin, G., & Malanowski, J. (1993) · Progress in Brain Research · doi:10.1016/s0079-6123(08)62429-2 · Cited by 301
KOIKE, H., Tomioka, S., Sorimachi, H., Saido, T. C., Maruyama, K., Okuyama, A., Fujisawa‐Sehara, A., Ohno, S., Suzuki, K., & Ishiura, S. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3430371 · Cited by 278
Nitsch, R. M., Farber, S. A., Growdon, J. H., & Wurtman, R. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5191 · Cited by 244
Schrattenholz, A., Pereira, E. F., Roth, U., Weber, K. H., Albuquerque, E. X., & Maelicke, A. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08675-4 · Cited by 226
DeKosky, D. S. T., Harbaugh, R. E., Schmitt, F. A., Bakay, R. A. E., Chui, H. C., Knopman, D. S., Reeder, T. M., Shetter, A. G., Senter, H. J., Markesbery, W. R., et al. (1992) · Annals of Neurology · doi:10.1002/ana.410320505 · Cited by 224
Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimer's Disease
Bai, D. L., Tang, X. C., & He, X. C. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003375281 · Cited by 216
Capsoni, S., Giannotta, S., & Cattaneo, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192442999 · Cited by 214
Takada, Y., Yonezawa, A., Kume, T., Katsuki, H., Kaneko, S., Sugimoto, H., & Akaike, A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.050104 · Cited by 208
Shaw, K. T. Y., Utsuki, T., Rogers, J., Yu, Q.-S., Sambamurti, K., Brossi, A., Ge, Y.-W., Lahiri, D. K., & Greig, N. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131152998 · Cited by 205
Phenserine and ring C hetero‐analogues: Drug candidates for the treatment of Alzheimer's disease
Greig, N. H., Pei, X., Soncrant, T. T., Ingram, D. K., & Brossi, A. (1995) · Medicinal Research Reviews · doi:10.1002/med.2610150103 · Cited by 192
Wolf, B. A., Wertkin, A. M., Jolly, Y. C., Yasuda, R. P., Wolfe, B. B., Konrad, R. J., Manning, D., Ravi, S., Williamson, J. R., & Lee, V. M.-Y. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.9.4916 · Cited by 191
Donepezil: A Review of its Use in Alzheimer??s Disease
Dooley, M., & Lamb, H. M. (2000) · Drugs & Aging · doi:10.2165/00002512-200016030-00005 · Cited by 189
Rivastigmine: A Review of its Use in Alzheimer??s Disease
Spencer, C. M., & Noble, S. (1998) · Drugs & Aging · doi:10.2165/00002512-199813050-00005 · Cited by 187
Petit, A., Bihel, F., da Costa, C. A., Pourquié, O., Checler, F., & Kraus, J.-L. (2001) · Nature Cell Biology · doi:10.1038/35074581 · Cited by 178
Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
Gasparini, L., Racchi, M., Binetti, G., Trabucchi, M., Solerte, S. B., Alkon, D., Etcheberrigaray, R., Gibson, G., Blass, J., Paoletti, R., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.1.17 · Cited by 175
Self-citationALZHEIMER'S DISEASE AND RELATED DISORDERS
Raskind, M. A., & Peskind, E. R. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70341-2 · Cited by 161
Regulated secretion of beta-amyloid precursor protein in rat brain
Farber, S., Nitsch, R., Schulz, J., & Wurtman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07442.1995 · Cited by 158
Cholinesterase inhibitors increase secretion of APPs in rat brain cortex
Mori, F., Lai, C.-C., Fusi, F., & Giacobini, E. (1995) · Neuroreport · doi:10.1097/00001756-199503000-00012 · Cited by 157
Xiao, X., Zhang, H., & Tang, X. C. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.10075 · Cited by 155
Chyung, A. S. C., Greenberg, B., Cook, D. G., Doms, R. W., & Lee, V. M. ‐. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.3.671 · Cited by 150
The Role of Presenilins in γ-Secretase Activity
Wolfe, M. S., & Haass, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r000026200 · Cited by 141
Wang, R., Zhang, H., & Tang, X. C. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01030-5 · Cited by 139
Haring, R., Fisher, A., Marciano, D., Pittel, Z., Kloog, Y., Zuckerman, A., Eshhar, N., & Heldman, E. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052094.x · Cited by 122
Tacrine alters the secretion of the beta‐amyloid precursor protein in cell lines
Lahiri, D. K., Lewis, S., & Farlow, M. R. (1994) · Journal of Neuroscience Research · doi:10.1002/jnr.490370612 · Cited by 118
Drug treatments for Alzheimer's disease: Raise clinical and ethical problems
Kelly, C., Harvey, R. J., & Cayton, H. (1997) · BMJ · doi:10.1136/bmj.314.7082.693 · Cited by 111
Yogev‐Falach, M., Amit, T., Bar‐Am, O., Weinstock, M., & Youdim, M. B. H. (2002) · The FASEB Journal · doi:10.1096/fj.02-0198fje · Cited by 110
Desdouits‐Magnen, J., Desdouits, F., Takeda, S., Syu, L.-J., Saltiel, A. R., Buxbaum, J. D., Czernik, A. J., Nairn, A. C., & Greengard, P. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70020524.x · Cited by 109
Capsoni, S., Giannotta, S., & Cattaneo, A. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1163 · Cited by 103
Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer’ disease
Giacobini, E. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_17 · Cited by 100
Tacrine and donepezil attenuate the neurotoxic effect of Aβ(25-35) in rat PC12 cells
Svensson, A., & Nordberg, A. K. (1998) · Neuroreport · doi:10.1097/00001756-199805110-00050 · Cited by 100
The pharmacology of donepezil: a new treatment for Alzheimer’s disease
Wilkinson, D. G. (1999) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.1.121 · Cited by 97
Endogenous β-amyloid production in presenilin-deficient embryonic mouse fibroblasts
Armogida, M., Petit-Paitel, A., Vincent, B., Scarzello, S., da Costa, C. A., & Checler, F. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1030 · Cited by 96
Donepezil for Alzheimer's Disease: Pharmacodynamic, Pharmacokinetic, and Clinical Profiles
Shigeta, M., & Homma, A. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00204.x · Cited by 94
Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD
Padovani, A., Pastorino, L., Borroni, B., Colciaghi, F., Rozzini, L., Monastero, R., Perez, J., Pettenati, C., Mussi, M., Parrinello, G., et al. (2001) · Neurology · doi:10.1212/wnl.57.12.2243 · Cited by 92
Advances in the pharmacotherapy of Alzheimer's disease.
Gauthier, S. G. (2002) · Europe PMC (PubMed Central) · Cited by 92
Gottwald, M. D., & Rozanski, R. I. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1673 · Cited by 91
Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury
Xiao, X., Yang, J. W., & Tang, X. C. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00695-3 · Cited by 90
Comorbidity in social anxiety disorder: impact on disease burden and management.
Tariot, P. N. (1998) · PubMed · Cited by 89
Xiao, X., Wang, R., Han, Y., & Tang, X. C. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01088-0 · Cited by 85
Borroni, B., Colciaghi, F., Pastorino, L., Pettenati, C., Cottini, E., Rozzini, L., Monastero, R., Lenzi, G. L., Cattabeni, F., Luca, M. D., et al. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.442 · Cited by 82
Slack, B. E., Breu, J., Petryniak, M. A., Srivastava, K., & Wurtman, R. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.14.8337 · Cited by 81
Cholinesterase Inhibitors Stabilize Alzheimer Disease
Giacobini, E. (2000) · Neurochemical Research · doi:10.1023/a:1007679709322 · Cited by 78
Slack, B. E. (2000) · Biochemical Journal · doi:10.1042/bj3480381 · Cited by 78
Do Cholinesterase Inhibitors Have Disease-Modifying Effects in Alzheimer??s Disease?
Giacobini, E. (2001) · CNS Drugs · doi:10.2165/00023210-200115020-00001 · Cited by 78
The secretion of amyloid β-peptides is inhibited in the tacrine-treated human neuroblastoma cells
Lahiri, D. K., Farlow, M. R., & Sambamurti, K. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00236-8 · Cited by 75
Gardella, J. E., Ghiso, J. A., Gorgone, G., Marratta, D., Kaplan, A., Frangione, B., & Gorevic, P. D. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80927-1 · Cited by 73
Akasofu, S., Kosasa, T., Kimura, M., & Kubota, A. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01865-x · Cited by 72
The pharmacology of amyloid precursor protein processing
Racchi, M., & Govoni, S. (2003) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00158-4 · Cited by 72
Self-citationThe experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics
Greig, N. H., Micheli, E. D., Holloway, H. W., Yu, Q.-S., Utsuki, T., Perry, T., Ingram, D. K., Deutsch, J., Lahiri, D. K., & Soncrant, T. T. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00311.x · Cited by 70
Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen–glucose deprivation
Zhou, J., Fu, Y., & Tang, X. C. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01855-9 · Cited by 70
Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia ischemia
Wang, L. S., Zhou, J., Shao, X. M., & Tang, X. C. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02977-3 · Cited by 65
Cholinergic therapy in dementia
Whitehouse, P. J. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04254.x · Cited by 63
Racchi, M., Sironi, M., Caprera, A., König, G., & Govoni, S. M. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000878 · Cited by 62
Self-citationPreclinical Pharmacology of Metrifonate
Jann, M. W. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03879.x · Cited by 61
Liu, L., Ikonen, S., Heikkinen, T., Tapiola, T., Groen, T. V., & Tanila, H. (2002) · Experimental Neurology · doi:10.1006/exnr.2001.7819 · Cited by 59
Pákáski, M., Rakonczay, Z., & Kása, P. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(00)00091-7 · Cited by 58
Zhang, H., Liang, Y. Q., Tang, X. C., He, X., & Bai, D. L. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02437-5 · Cited by 56
Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism
Racchi, M., & Govoni, S. M. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01380-2 · Cited by 56
Self-citationThe multiple paradoxes of presenilins
Checler, F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00244.x · Cited by 49
Role of protein kinase Cα in the regulated secretion of the amyloid precursor protein
Racchi, M., Mazzucchelli, M., Pascale, A., Sironi, M., & Govoni, S. M. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001204 · Cited by 44
Self-citationLahiri, D. K., & Farlow, M. R. (1996) · Journal of Molecular Neuroscience · doi:10.1007/bf02736847 · Cited by 44
Racchi, M., Solano, D. C., Sironi, M., & Govoni, S. M. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722464.x · Cited by 43
Self-citationBeach, T. G., Kuo, Y., Schwab, C., Walker, D. G., & Roher, A. E. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02076-6 · Cited by 42
Lahiri, D. K., Farlow, M. R., Nürnberger, J. I., & Greig, N. H. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48495.x · Cited by 41
Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders
Desai, A. K., & Grossberg, G. T. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.4.653 · Cited by 41
Current status and new developments with galantamine in the treatment of Alzheimer’s disease
Tariot, P. N. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.12.2027 · Cited by 35
Iijima, S., Greig, N. H., Garofalo, P., Spangler, E. L., Heller, B., Brossi, A. R., & Ingram, D. K. (1993) · Psychopharmacology · doi:10.1007/bf02244888 · Cited by 32
Basun, H., Nilsberth, C., Eckman, C. B., Lannfelt, L., & Younkin, S. G. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000063605 · Cited by 31
Huperzine A protects rat pheochromocytoma cells against oxygen–glucose deprivation
Zhou, J., Fu, Y., & Tang, X. (2001) · Neuroreport · doi:10.1097/00001756-200107200-00007 · Cited by 27
Metrifonate: Overview of Safety and Efficacy
Cummings, J. L. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03877.x · Cited by 26
Lahiri, D. K. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90581-9 · Cited by 23
Mazzucchelli, M., Porrello, E., Villetti, G., Pietra, C., Govoni, S. M., & Racchi, M. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0006-x · Cited by 23
Self-citationPákáski, M., Rakonczay, Z., Fakla, I., Papp, H., & Kása, P. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02120-x · Cited by 22
CHF2819: Pharmacological Profile of a Novel Acetylcholinesterase Inhibitor
Trabace, L., Cassano, T., Loverre, A., Steardo, L., & Cuomo, V. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00215.x · Cited by 15
First Clinical Evaluation of Ganstigmine in Patients With Probable Alzheimer's Disease
Jhee, S. S., Fabbri, L., Piccinno, A., Monici, P., Moran, S. E., Zarotsky, V., Tan, E. Y., Frackiewicz, E. J., & Shiovitz, T. M. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200305000-00011 · Cited by 10
Cited by
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
Zemek, F., Drtinova, L., Nepovimova, E., Sepsova, V., Korabecny, J., Klimes, J., & Kuca, K. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.914168 · Cited by 299
Impedance Spectroscopy: A Powerful Tool for Rapid Biomolecular Screening and Cell Culture Monitoring
K'Owino, I. O., & Sadik, O. A. (2005) · Electroanalysis · doi:10.1002/elan.200503371 · Cited by 292
Bachovchin, D. A., Ji, T., Li, W., Simon, G. M., Blankman, J. L., Adibekian, A., Hoover, H., Niessen, S., & Cravatt, B. F. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011663107 · Cited by 274
A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease Pathology
Eubanks, L. M., Rogers, C. J., Beuscher, Koob, G. F., Olson, A. J., Dickerson, T. J., & Janda, K. D. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060066m · Cited by 268
Cholinesterase Inhibitors and Beyond
Pepeu, G., & Giovannini, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602861 · Cited by 209
Metadata
- Authors
- RACCHI, M.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 50
- Issue
- 4
- Pages
- 441-451
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2072219894
- Cited by
- 288
- References
- 103
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.